Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
 
Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
  
 
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530 
     free
  
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531 
     free
      free 
   English Wikipedia
  Nephropedia Template TP (
  Twit Text
 
  DeepDyve Pubget Overpricing |    
 
  lüll Current pacemaker and defibrillator therapy Trappe HJ; Gummert JDtsch Arztebl Int  2011[May]; 108 (21): 372-9; quiz 380BACKGROUND: Pacemakers have been available for 50 years, and implantable cardiac  defibrillators for 25. Clear indications for each have been established on the  basis of data from randomized clinical trials (RCTs). METHODS: This review  article is the product of a collaborative effort by a cardiologist and a cardiac  surgeon. The authors arrived at a consensus through a selective review of the  literature, with special attention to randomized controlled trials and registry  data. RESULTS: Atrioventricular (AV) block only rarely necessitates permanent  pacemaker stimulation after inferior myocardial infarction, of which it is a rare  (12% to 20%) and often transient accompaniment. AV block is more common, however,  in anterior wall infarction (frequency ca. 5%), and often necessitates permanent  pacemaker therapy in such cases. Pacemaker complications are rare; they include  oversensing (the detection of impulse noise) (0.7%), undersensing (the failure to  detect impulses) (3.8%), electrode fractures (3.8%), isolation defects (3.4%),  perforation (<1%), dislocation (<1%), and infection (<1% to 12%). Many RCTs have  confirmed that defibrillators are effective in the prevention of sudden cardiac  death (SCD): they lower the risk of SCD by 20% to 30% in primary prevention and  by 20% to 40% in secondary prevention. Cardiac resynchronization therapy improves  the clinical manifestations and outcome of patients with congestive heart  failure, with a relative risk reduction (RR) of 20% to 40%, even among patients  in NYHA classes I and II (RR ca. 40%). Implantable defibrillators only rarely  cause problems or complications in either the short or the long term. Emotional  disturbances, including anxiety, are a rare side effect, occurring in less than  1% of cases. CONCLUSION: Pacemakers and implantable defibrillators are  well-established electrotherapeutic devices that are highly effective and have  only rare complications.|*Defibrillators, Implantable/adverse effects[MESH]|*Pacemaker, Artificial/adverse effects[MESH]|Anterior Wall Myocardial Infarction/*complications[MESH]|Arrhythmias, Cardiac/*therapy[MESH]|Atrioventricular Block/*therapy[MESH]|Bradycardia/mortality/therapy[MESH]|Cardiac Resynchronization Therapy[MESH]|Cooperative Behavior[MESH]|Death, Sudden, Cardiac/*prevention & control[MESH]|Equipment Failure Analysis[MESH]|Germany[MESH]|Heart Failure/mortality/therapy[MESH]|Humans[MESH]|Interdisciplinary Communication[MESH]|Practice Guidelines as Topic[MESH]|Randomized Controlled Trials as Topic[MESH]|Registries[MESH]|Risk[MESH]|Survival Rate[MESH]|Tachycardia/mortality/therapy[MESH] |